The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers.
Study Design
- 연구 유형
- Randomized Controlled Trial
- 중재
- The effects of glycine on subjective daytime performance in partially sleep-restricted healthy volunteers. Glycine 3 g before bedtime
- 대조군
- Placebo
- 효과 방향
- Positive
- 비뚤림 위험
- Moderate
Abstract
Approximately 30% of the general population suffers from insomnia. Given that insomnia causes many problems, amelioration of the symptoms is crucial. Recently, we found that a non-essential amino acid, glycine subjectively and objectively improves sleep quality in humans who have difficulty sleeping. We evaluated the effects of glycine on daytime sleepiness, fatigue, and performances in sleep-restricted healthy subjects. Sleep was restricted to 25% less than the usual sleep time for three consecutive nights. Before bedtime, 3 g of glycine or placebo were ingested, sleepiness, and fatigue were evaluated using the visual analog scale (VAS) and a questionnaire, and performance were estimated by personal computer (PC) performance test program on the following day. In subjects given glycine, the VAS data showed a significant reduction in fatigue and a tendency toward reduced sleepiness. These observations were also found via the questionnaire, indicating that glycine improves daytime sleepiness and fatigue induced by acute sleep restriction. PC performance test revealed significant improvement in psychomotor vigilance test. We also measured plasma melatonin and the expression of circadian-modulated genes expression in the rat suprachiasmatic nucleus (SCN) to evaluate the effects of glycine on circadian rhythms. Glycine did not show significant effects on plasma melatonin concentrations during either the dark or light period. Moreover, the expression levels of clock genes such as Bmal1 and Per2 remained unchanged. However, we observed a glycine-induced increase in the neuropeptides arginine vasopressin and vasoactive intestinal polypeptide in the light period. Although no alterations in the circadian clock itself were observed, our results indicate that glycine modulated SCN function. Thus, glycine modulates certain neuropeptides in the SCN and this phenomenon may indirectly contribute to improving the occasional sleepiness and fatigue induced by sleep restriction.
Full Text
Figures
Figure 1
Subjective sleepiness and fatigue scores during daytime hours are compared between glycine and placebo conditions in partially sleep-restricted healthy volunteers.
chart
Figure 2
Cognitive performance measures following glycine or placebo ingestion under sleep restriction are presented, assessing the amino acid's effects on daytime function.
chart
Figure 3
Psychomotor vigilance task results compare reaction times and lapses between glycine-supplemented and placebo participants during the sleep restriction protocol.
chart
Figure 4
Overall subjective daytime performance ratings summarize glycine's reported benefits on next-day functioning in sleep-deprived individuals.
chartTables
Table 1
| 18S | Forward: CGCGGTTCTATTTTGTTGGTTTTCG |
| Reverse: CTGATCGTCTTCGAACCTCCGACTT | |
| Bmal1 | Forward: AACCCGTGGACCAAGGAAGT |
| Reverse: GTGAGCTGTGGGAAGGTTGG | |
| Per2 | Forward: CATGGCCAGTGTGCAGAGAG |
| Reverse: GAGGCCACCAAACAGACAGG | |
| AVP | Forward: TCGCCATGATGCTCAACACT |
| Reverse: GCCTCCTCTTGGGCAGTTCT | |
| VIP | Forward: GTTCCTGGCGATCCTGACAC |
| Reverse: AGGCCAGCGACTGTGAGAAC |
Table 1
| Results | Statistics | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | Glycine | Treatment | Treatment × time | |||||||
| 10:00 | 14:00 | 18:00 | 10:00 | 14:00 | 18:00 | |||||
| Sleepiness; Sleepy: 100 – alert: 0 | 48.1 (5.65) | 52.9 (10.51) | 51 (6.97) | 32.7 (7.94) | 36 (6.78) | 45.6 (8.71) | 3.82 | 0.098 | 0.26 | 0.774 |
| Fatigue; Extremely fatigued: 100 – vigorous: 0 | 48.3 (4.97) | 53.1 (6.2) | 59.6 (8.14) | 33.6 (4.6) | 35.4 (8.62) | 51 (9.73) | 9.36 | 0.022 | 0.48 | 0.628 |
| Factor I – drowsiness | 11.7 (1.46) | 11.7 (1.55) | 10.1 (1.79) | 8 (0.79) | 7.4 (0.84) | 8.9 (0.99) | 5.03 | 0.066 | 0.38 | 0.691 |
| Factor II – instability | 9.3 (0.84) | 9.6 (1.32) | 8 (1.13) | 6.6 (0.43) | 7 (1) | 7.6 (1.32) | 4.77 | 0.072 | 3.35 | 0.07 |
| Factor III – uneasiness | 9 (0.98) | 8.9 (1.18) | 9 (2.36) | 7.6 (0.43) | 7.4 (0.81) | 8.4 (1.02) | 1.55 | 0.259 | 0.25 | 0.78 |
| Factor IV – local pain or dullness | 7.7 (0.64) | 7.4 (0.53) | 7.1 (0.74) | 6.6 (0.57) | 6.4 (0.53) | 6.7 (0.47) | 3.16 | 0.125 | 0.51 | 0.611 |
| Factor V – eyestrains | 9.4 (1.51) | 8.9 (1.53) | 9.6 (1.17) | 7.4 (1.09) | 8 (1.18) | 8.4 (1.43) | 4.41 | 0.081 | 0.61 | 0.559 |
| Total score; extremely fatigued: 125 – vigorous: 25 | 47 (4.24) | 46.1 (4.93) | 43.7 (6.17) | 36.1 (1.75) | 36.3 (3.21) | 40 (4.21) | 4.44 | 0.08 | 1.2 | 0.334 |
Table 2
| Day 1 | Day 3 | |||||||
|---|---|---|---|---|---|---|---|---|
| Treatment | Treatment × time | Treatment | Treatment × time | |||||
| Correct response | 1.35 | 0.289 | 0.18 | 0.838. | 1.36 | 0.288 | 1.4 | 0.284 |
| Reaction time | 3.78 | 0.1 | 1.78 | 0.211 | 0.02 | 0.892 | 1.09 | 0.369 |
| Correct response | 2.84 | 0.143 | 1.41 | 0.283 | 0.4 | 0.55 | 0.71 | 0.513 |
| Reaction time | 21.69 | 0.003 | 0.66 | 0.536 | 6.01 | 0.05 | 0.07 | 0.937 |
| Correct response | 4.57 | 0.076 | 2.65 | 0.111 | 1.54 | 0.261 | 4.08 | 0.044 |
| Reaction time | 1.7 | 0.24 | 1 | 0.397 | 0.73 | 0.426 | 0.53 | 0.602 |
| Correct response | 0.0004 | 0.984 | 2.1 | 0.165 | 0.55 | 0.486 | 0.89 | 0.435 |
| Reaction time | 0.05 | 0.838 | 0.19 | 0.831 | 0.07 | 0.795 | 1.32 | 0.304 |
References
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
Used In Evidence Reviews
Similar Papers
Journal of sleep research · 2017
European guideline for the diagnosis and treatment of insomnia.
Chronobiology international · 2012
Circadian typology: a comprehensive review.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
Movement disorders : official journal of the Movement Disorder Society · 2011
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
Cell · 1981
Regulation of terminal differentiation of cultured human keratinocytes by vitamin A.
Journal of neuroendocrinology · 2003